Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd (TAK)

Takeda Pharmaceutical Co. Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,163,312
  • Shares Outstanding, K 3,152,748
  • Annual Sales, $ 30,279 M
  • Annual Income, $ 407,020 K
  • 60-Month Beta 1.00
  • Price/Sales 1.98
  • Price/Cash Flow 5.48
  • Price/Book 1.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +178,292.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.44 +10.49%
on 05/07/20
19.55 -1.43%
on 05/26/20
+0.62 (+3.32%)
since 04/27/20
3-Month
12.43 +55.03%
on 03/18/20
19.55 -1.43%
on 05/26/20
+1.64 (+9.30%)
since 02/27/20
52-Week
12.43 +55.03%
on 03/18/20
20.92 -7.91%
on 11/19/19
+1.56 (+8.81%)
since 05/24/19

Most Recent Stories

More News
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

BMY : 60.40 (+0.13%)
SGEN : 152.97 (+0.82%)
MBRX : 1.0800 (+0.93%)
TAK : 19.27 (-0.67%)
Takeda Accelerates Transformation: Solid FY2019 Results, Confidence in FY2020 Growth Momentum

Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) ("Takeda") today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical...

TKPYY : 16.5900 (-0.90%)
TAK : 19.27 (-0.67%)
NYSE Board Advisory Council Welcomes Eight New Members

The New York Stock Exchange (NYSE), a wholly-owned subsidiary of Intercontinental Exchange (NYSE: ICE), welcomed eight new members to the NYSE Board Advisory Council, which identifies and connects diverse...

BKD : 3.84 (+5.21%)
BG : 39.36 (+4.35%)
ED : 71.25 (+0.08%)
BEN : 19.35 (+2.06%)
HPQ : 17.12 (+0.35%)
NYT : 39.44 (+0.36%)
SPGI : 315.43 (+0.99%)
TAK : 19.27 (-0.67%)
ICE : 92.83 (-1.49%)
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.

JNJ : 144.89 (+0.23%)
PFE : 37.41 (-0.21%)
MYOV : 12.48 (+0.56%)
TAK : 19.27 (-0.67%)
These 10 Drug Companies are Testing a Coronavirus Vaccine

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

JNJ : 144.89 (+0.23%)
REGN : 544.01 (-0.22%)
SNY : 47.49 (+0.47%)
GILD : 74.90 (+2.35%)
MRNA : 52.18 (-9.58%)
GSK : 40.94 (+0.47%)
NVAX : 45.47 (-5.61%)
INO : 13.19 (-8.78%)
VIR : 32.20 (-4.37%)
TAK : 19.27 (-0.67%)
Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 19.27 (-0.67%)
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 52.18 (-9.58%)
TAK : 19.27 (-0.67%)
PFE : 37.41 (-0.21%)
LLY : 145.70 (-1.53%)
AZN : 52.47 (-1.21%)
MRK : 77.55 (+0.38%)
Francois Nader, M.D., Joins Moderna's Board of Directors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

SHPG : 179.20 (+4.10%)
MRNA : 52.18 (-9.58%)
TAK : 19.27 (-0.67%)
SNY : 47.49 (+0.47%)
XLRN : 99.51 (+1.11%)
PRVL : 16.90 (-2.42%)
ALXN : 106.14 (+3.25%)
AAAP : 81.63 (+0.16%)
BXLT : 46.02 (-0.39%)
CMTA : 26.35 (-0.11%)
TRVN : 1.3900 (-0.71%)
NOVN : 0.4174 (-0.62%)
AZN : 52.47 (-1.21%)
MRK : 77.55 (+0.38%)
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

JNJ : 144.89 (+0.23%)
RHHBY : 43.0900 (-2.36%)
HALO : 23.97 (-1.40%)
TAK : 19.27 (-0.67%)
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 60.40 (+0.13%)
LLY : 145.70 (-1.53%)
ACAD : 50.63 (-1.06%)
CHRS : 19.15 (+12.91%)
CELG : 108.24 (+0.10%)
BIIB : 301.46 (+1.89%)
INCY : 98.22 (-0.47%)
ADPT : 39.08 (-0.79%)
ALEC : 32.74 (+3.48%)
NGM : 20.29 (-1.74%)
TAK : 19.27 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade TAK with:

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

2nd Resistance Point 19.62
1st Resistance Point 19.44
Last Price 19.27
1st Support Level 19.05
2nd Support Level 18.84

See More

52-Week High 20.92
Last Price 19.27
Fibonacci 61.8% 17.68
Fibonacci 50% 16.68
Fibonacci 38.2% 15.68
52-Week Low 12.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar